Search results
Sarepta (SRPT) Stock Up 76.8% in Three Months: Here's Why
Zacks via Yahoo Finance· 2 years agoSarepta Therapeutics (SRPT) is progressing with the development of its pipeline, which focuses on...
Why Sarepta's (SRPT) Stock Price Moved Up 17% on Tuesday
Zacks via Yahoo Finance· 5 months agoSarepta (SRPT) surges after its CEO made positive comments on the label expansion filing for the...
Sarepta data show new Duchenne drug’s potency, but highlight side effects
BioPharma Dive via Yahoo Finance· 4 months agoA successor medicine to Sarepta's Exondys 51 appeared better at boosting dystrophin protein...
Sarepta's (SRPT) DMD Gene Therapy Gets Endorsed by FDA Panel
Zacks via Yahoo Finance· 1 year agoThe FDA's CTGTAC narrowly recommends granting accelerated approval to Sarepta's (SRPT) DMD gene...
Sarepta (SRPT) Q2 Earnings Miss, DMD Drugs' Sales Robust
Zacks via Yahoo Finance· 2 years agoStrong demand for Sarepta's (SRPT) DMD drugs boosts the top line in the second quarter. However, the...
Sarepta (SRPT) Down on Clinical Hold on DMD Candidate SRP-5051
Zacks via Yahoo Finance· 2 years agoThe FDA places Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, on clinical hold, following...
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
Motley Fool via Yahoo Finance· 4 months agoIn biotech, it's often difficult to tell whether bad news for one company will also be bad news for...
A Comprehensive Look at Sarepta's Growth and Innovation
GuruFocus.com via Yahoo Finance· 2 months agoSarepta Therapeutics, Inc. (NASDAQ:SRPT) is an American pharmaceutical company leading the global...
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
Motley Fool via Yahoo Finance· 4 months agoSarepta Therapeutics (NASDAQ: SRPT) and Vertex Pharmaceuticals (NASDAQ: VRTX) have a lot in common:...
Is It Too Late to Buy Sarepta Therapeutics Stock?
Motley Fool via Yahoo Finance· 3 months agoSarepta Therapeutics (NASDAQ: SRPT), a midcap biotech company, was riding high 18 months ago. The company was awaiting a crucial regulatory approval from...
